Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Nigel Bark MD, Bronx Psychiatric Center Identifier:
First received: January 14, 2009
Last updated: July 20, 2015
Last verified: July 2015
This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Condition Intervention
Drug: Allopurinal

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

Resource links provided by NLM:

Further study details as provided by Bronx Psychiatric Center:

Primary Outcome Measures:
  • Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia [ Time Frame: baseline and 4 weeks ]
    Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)

Secondary Outcome Measures:
  • Simpson Angus Scale for Parkinsonism [ Time Frame: baseline and 4 weeks ]
    Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)

Enrollment: 10
Study Start Date: November 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allopurinal treatment
Allopurinal 300mg once daily by mouth for four weeks
Drug: Allopurinal
300mg once daily by mouth for four weeks


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion Criteria:

  • Over 65
  • Renal or liver disease
  • Diabetes
  • Hypertension
  • Taking thiazides or ACE inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00823199

Sponsors and Collaborators
Bronx Psychiatric Center
Principal Investigator: Nigel Bark, MD Bronx Psychiatric Center
  More Information

Responsible Party: Nigel Bark MD, Director Schizophrenia Research, Bronx Psychiatric Center Identifier: NCT00823199     History of Changes
Other Study ID Numbers: ICFV12/02
Study First Received: January 14, 2009
Results First Received: April 25, 2012
Last Updated: July 20, 2015

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs processed this record on April 25, 2017